T.I. Eliseeva (1), E.V. Tush (1), I.I. Balabolkin (2), V.A. Bulgakova (2), N.A. Novikova (3), E.S. Zastelo (3), P.V. Trushanina (1), O.V. Khaletskaya (1), Т.Е. Potemina (1)

1) FSBEI HE “Nizhny Novgorod State Medical Academy” of RMH, Nizhny Novgorod; 2) Scientific Center for Children’s Health, Moscow; 3) SBHCI NR “Children’s City Clinical Hospital № 1”, Nizhny Novgorod
Currently, adverse drug reactions (ADRs) are a big problem due to the high prevalence and the potential severity of their outcomes. There are type A (dose-dependent, more common) and type B (unpredictable, often more severe and clinically problematic) ADRs. The children’s population is more vulnerable to the development of ADRs due to the immaturity of the systems involved in the absorption, metabolism, transport and elimination of drugs, which should be taken into account during prescription of pharmacotherapy in children.

About the Autors

Corresponding author: T.I. Eliseeva – MD, Associate Professor at the Department of Hospital Pediatrics FSBEI HE NizhSMA, Nizhny Novgorod; e-mail:

Similar Articles

Бионика Медиа